drugset / Trial / NCT05221385
Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and tolerability of gentulizumab, an anti-CD47 Monoclonal Antibody, in participants with solid tumors and non-Hodgkin lymphoma.
Timeline
- Start
- 2021-04-12
- Primary completion
- 2023-05-30
- Completion
- 2023-10-27
Outcome
Outcome not reported
Stopped (Business): “Due to changes in the sponsor's research strategy”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gentulizumab | Monoclonal antibody | 0.1 mg/kg | Intravenous |
| Subject | Gentulizumab | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | Gentulizumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Gentulizumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Gentulizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Gentulizumab | Monoclonal antibody | 30 mg/kg | Intravenous |
| Subject | Gentulizumab | Monoclonal antibody | 45 mg/kg | Intravenous |